M Hiligsmann1, S Maggi2, N Veronese3, L Sartori4, J-Y Reginster5,6. 1. Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands. m.hiligsmann@maastrichtuniversity.nl. 2. CNR-NI, Aging Branch-Padua, Padua, Italy. 3. Department of Geriatrics, University of Palermo, Palermo, Italy. 4. Department of Medicine, University of Padua, Padua, Italy. 5. Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. 6. Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Abstract
The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. INTRODUCTION: To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. METHODS: A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered soluble ALN compared with generic ALN, denosumab, zoledronic acid and no treatment. Pooled efficacy data derived from the NICE network meta-analysis were used for bisphosphonate treatments. Two treatment duration scenarios were assessed: 1 year using persistence data derived from an Italian prospective observational study including 144 and 216 postmenopausal osteoporotic women on buffered soluble ALN and oral ALN, respectively, and 3 years. Analyses were conducted for women 60-80 years of age with a bone mineral density T-score ≤ - 3.0 or with existing vertebral fractures. RESULTS: In all simulated populations, buffered soluble ALN was dominant (more QALYs, lower costs) compared to denosumab. The cost per QALY gained of buffered soluble ALN compared to generic ALN and no treatment always falls below €20,000 per QALY gained. In the 1-year treatment scenario, zoledronic acid was associated with more QALY than buffered soluble ALN but the cost per QALY gained of zoledronic acid compared with buffered soluble ALN was always higher than €70,000, while buffered soluble ALN was dominant in the 3-year treatment scenario. CONCLUSION: This study suggests that buffered soluble ALN represents a cost-effective strategy compared with relevant alternative treatments for postmenopausal osteoporosis women in Italy aged 60 years and over.
The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. INTRODUCTION: To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporoticwomen in Italy. METHODS: A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered soluble ALN compared with generic ALN, denosumab, zoledronic acid and no treatment. Pooled efficacy data derived from the NICE network meta-analysis were used for bisphosphonate treatments. Two treatment duration scenarios were assessed: 1 year using persistence data derived from an Italian prospective observational study including 144 and 216 postmenopausal osteoporoticwomen on buffered soluble ALN and oral ALN, respectively, and 3 years. Analyses were conducted for women 60-80 years of age with a bone mineral density T-score ≤ - 3.0 or with existing vertebral fractures. RESULTS: In all simulated populations, buffered soluble ALN was dominant (more QALYs, lower costs) compared to denosumab. The cost per QALY gained of buffered soluble ALN compared to generic ALN and no treatment always falls below €20,000 per QALY gained. In the 1-year treatment scenario, zoledronic acid was associated with more QALY than buffered soluble ALN but the cost per QALY gained of zoledronic acid compared with buffered soluble ALN was always higher than €70,000, while buffered soluble ALN was dominant in the 3-year treatment scenario. CONCLUSION: This study suggests that buffered soluble ALN represents a cost-effective strategy compared with relevant alternative treatments for postmenopausal osteoporosiswomen in Italy aged 60 years and over.
Authors: Mickaël Hiligsmann; Silvia M Evers; Wafa Ben Sedrine; John A Kanis; Bram Ramaekers; Jean-Yves Reginster; Stuart Silverman; Caroline E Wyers; Annelies Boonen Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981
Authors: L A Hodges; S M Connolly; J Winter; T Schmidt; H N E Stevens; M Hayward; C G Wilson Journal: Int J Pharm Date: 2012-05-04 Impact factor: 5.875
Authors: M R McClung; P D Miller; J P Brown; J Zanchetta; M A Bolognese; C L Benhamou; A Balske; D E Burgio; J Sarley; L K McCullough; R R Recker Journal: Osteoporos Int Date: 2011-09-27 Impact factor: 4.507
Authors: Fredrik Borgström; Linda Karlsson; Gustav Ortsäter; Nicolas Norton; Philippe Halbout; Cyrus Cooper; Mattias Lorentzon; Eugene V McCloskey; Nicholas C Harvey; Muhamamd K Javaid; John A Kanis Journal: Arch Osteoporos Date: 2020-04-19 Impact factor: 2.617
Authors: M Hiligsmann; J-Y Reginster; A N A Tosteson; S V Bukata; K G Saag; D T Gold; P Halbout; F Jiwa; E M Lewiecki; D Pinto; J D Adachi; N Al-Daghri; O Bruyère; M Chandran; C Cooper; N C Harvey; T A Einhorn; J A Kanis; D L Kendler; O D Messina; R Rizzoli; L Si; S Silverman Journal: Osteoporos Int Date: 2018-10-31 Impact factor: 4.507
Authors: M Hiligsmann; D Cornelissen; B Vrijens; B Abrahamsen; N Al-Daghri; E Biver; M L Brandi; O Bruyère; N Burlet; C Cooper; B Cortet; E Dennison; A Diez-Perez; A Gasparik; A Grosso; P Hadji; P Halbout; J A Kanis; J M Kaufman; A Laslop; S Maggi; R Rizzoli; T Thomas; S Tuzun; M Vlaskovska; J Y Reginster Journal: Osteoporos Int Date: 2019-08-07 Impact factor: 4.507
Authors: M Hiligsmann; N Li; C Cooper; J-Y Reginster; S Silverman; C Carswell; D Husereau Journal: Osteoporos Int Date: 2022-04-12 Impact factor: 5.071